245 related articles for article (PubMed ID: 32476809)
1. Double Antithrombotic versus Triple Antithrombotic Therapy in Patients with Atrial Fibrillation and Acute Coronary Syndrome.
Dharma S
Int J Angiol; 2020 Jun; 29(2):81-87. PubMed ID: 32476809
[TBL] [Abstract][Full Text] [Related]
2. Apixaban versus PhenpRocoumon: Oral AntiCoagulation plus antiplatelet tHerapy in patients with Acute Coronary Syndrome and Atrial Fibrillation (APPROACH-ACS-AF): Rationale and design of the prospective randomized parallel-group, open-label, blinded-endpoint, superiority, multicenter-trial of a triple therapy versus a dual therapy in patients with Atrial Fibrillation and Acute Coronary Syndrome undergoing coronary stenting.
Riesinger L; Strobl C; Leistner DM; Gori T; Akin I; Mehr M; Kellnar A; Mahabadi AA; Bogossian H; Block M; Edelmann F; Sarafoff N; Sibbing D; Ince H; Rassaf T; Mansmann U; Mehilli J; Kääb S; Hausleiter J; Massberg S; Wakili R
Int J Cardiol Heart Vasc; 2021 Aug; 35():100810. PubMed ID: 34258380
[TBL] [Abstract][Full Text] [Related]
3. The role of triple antithrombotic therapy in patients with atrial fibrillation undergoing percutaneous coronary intervention.
Fanaroff AC; Lopes RD
Prog Cardiovasc Dis; 2021; 69():11-17. PubMed ID: 34883097
[TBL] [Abstract][Full Text] [Related]
4. Safety and efficacy of double vs. triple antithrombotic therapy in patients with atrial fibrillation with or without acute coronary syndrome undergoing percutaneous coronary intervention: a collaborative meta-analysis of non-vitamin K antagonist oral anticoagulant-based randomized clinical trials.
Gargiulo G; Cannon CP; Gibson CM; Goette A; Lopes RD; Oldgren J; Korjian S; Windecker S; Esposito G; Vranckx P; Valgimigli M
Eur Heart J Cardiovasc Pharmacother; 2021 Apr; 7(FI1):f50-f60. PubMed ID: 33119069
[TBL] [Abstract][Full Text] [Related]
5. Non-Vitamin K Oral Anticoagulants (NOAC) Versus Vitamin K Antagonists (VKA) for Atrial Fibrillation with Elective or Urgent Percutaneous Coronary Intervention: A Meta-Analysis with a Particular Focus on Combination Type.
Eyileten C; Postula M; Jakubik D; Toma A; Mirowska-Guzel D; Patti G; Renda G; Siller-Matula JM
J Clin Med; 2020 Apr; 9(4):. PubMed ID: 32295160
[TBL] [Abstract][Full Text] [Related]
6. Intracranial haemorrhages vs. stent thromboses with direct oral anticoagulant plus single antiplatelet agent or triple antithrombotic therapy: a meta-analysis of randomized trials in atrial fibrillation and percutaneous coronary intervention/acute coronary syndrome patients.
Galli M; Andreotti F; Porto I; Crea F
Europace; 2020 Apr; 22(4):538-546. PubMed ID: 31942971
[TBL] [Abstract][Full Text] [Related]
7. Antithrombotic therapies in Canadian atrial fibrillation patients with concomitant coronary artery disease: Insights from the CONNECT AF + PCI-II program.
Chow JK; Bagai A; Tan MK; Har BJ; Yip AMC; Paniagua M; Elbarouni B; Bainey KR; Paradis JM; Maranda R; Cantor WJ; Eisenberg MJ; Dery JP; Madan M; Cieza T; Matteau A; Roth S; Lavi S; Glanz A; Gao D; Tahiliani R; Welsh RC; Kim HH; Robinson SD; Daneault B; Chong AY; Le May MR; Ahooja V; Gregoire JC; Nadeau PL; Laksman Z; Heilbron B; Yung D; Minhas K; Bourgeois R; Overgaard CB; Bonakdar H; Logsetty G; Lavoie AJ; De LaRochelliere R; Mansour S; Spindler C; Yan AT; Goodman SG;
J Cardiol; 2023 Aug; 82(2):153-161. PubMed ID: 36931433
[TBL] [Abstract][Full Text] [Related]
8. Risk of Stroke vs. Intracerebral Hemorrhage in Patients with Non-Valvular Atrial Fibrillation Undergoing Percutaneous Coronary Intervention: A Systematic Review and Meta-Analysis of Randomized Controlled Trials Comparing Dual vs. Triple Antithrombotic Therapy.
Desai A; Escamilla-Ocanas C; Dilip D; Saber H; Damani R
J Stroke Cerebrovasc Dis; 2021 Apr; 30(4):105654. PubMed ID: 33578352
[TBL] [Abstract][Full Text] [Related]
9. Atrial fibrillation in acute coronary syndrome: patient characteristics and appropriate utilisation of anti-thrombotic therapy in New Zealand (ANZACS-QI 39).
Ho CY; Nunn C; White J; Kerr A; Lee M
N Z Med J; 2020 Jul; 133(1519):41-54. PubMed ID: 32777794
[TBL] [Abstract][Full Text] [Related]
10. Bleeding and ischaemic outcomes in patients treated with dual or triple antithrombotic therapy: systematic review and meta-analysis.
Haller PM; Sulzgruber P; Kaufmann C; Geelhoed B; Tamargo J; Wassmann S; Schnabel RB; Westermann D; Huber K; Niessner A; Gremmel T
Eur Heart J Cardiovasc Pharmacother; 2019 Oct; 5(4):226-236. PubMed ID: 31198930
[TBL] [Abstract][Full Text] [Related]
11. Safety and efficacy outcomes of double vs. triple antithrombotic therapy in patients with atrial fibrillation following percutaneous coronary intervention: a systematic review and meta-analysis of non-vitamin K antagonist oral anticoagulant-based randomized clinical trials.
Gargiulo G; Goette A; Tijssen J; Eckardt L; Lewalter T; Vranckx P; Valgimigli M
Eur Heart J; 2019 Dec; 40(46):3757-3767. PubMed ID: 31651946
[TBL] [Abstract][Full Text] [Related]
12. Antithrombotic therapy in patients with atrial fibrillation and acute coronary syndrome and / or undergoing percutaneous coronary intervention.
Mihajlovic M; Marinkovic M; Kozieł M; Mujovic N; Lip GYH; Potpara TS
Kardiol Pol; 2020 Jun; 78(6):512-519. PubMed ID: 32543800
[TBL] [Abstract][Full Text] [Related]
13. Antithrombotic Strategies in Patients with Atrial Fibrillation and Acute Coronary Syndromes Undergoing Percutaneous Coronary Intervention.
De Luca L; Mistrulli R; Veneziano FA; Grigioni F; Volpe M; Musumeci F; Gabrielli D
J Clin Med; 2022 Jan; 11(3):. PubMed ID: 35159964
[TBL] [Abstract][Full Text] [Related]
14. Is triple antithrombotic therapy a safe option in patients with AF who receive drug-eluting stents?: a review article.
Alshahrani A; O'Nunain S
Egypt Heart J; 2023 Aug; 75(1):74. PubMed ID: 37639078
[TBL] [Abstract][Full Text] [Related]
15. Benefit of dual antithrombotic therapy with direct oral anticoagulants in patients with atrial fibrillation undergoing percutaneous coronary intervention: a systematic review and metaanalysis of randomized clinical trials.
Zoppellaro G; Marchese GM; Squizzato A; Denas G; Patti G; De Caterina R; Pengo V
Intern Emerg Med; 2020 Sep; 15(6):1093-1104. PubMed ID: 32617904
[TBL] [Abstract][Full Text] [Related]
16. Antithrombotic Management for Atrial Fibrillation Patients Undergoing Percutaneous Coronary Intervention or With Acute Coronary Syndrome: An Evidence-Based Update.
Zhao S; Hong X; Cai H; Liu M; Li B; Ma P
Front Cardiovasc Med; 2021; 8():660986. PubMed ID: 34262952
[TBL] [Abstract][Full Text] [Related]
17. Safety and Efficacy of Antithrombotic Strategies in Patients With Atrial Fibrillation Undergoing Percutaneous Coronary Intervention: A Network Meta-analysis of Randomized Controlled Trials.
Lopes RD; Hong H; Harskamp RE; Bhatt DL; Mehran R; Cannon CP; Granger CB; Verheugt FWA; Li J; Ten Berg JM; Sarafoff N; Gibson CM; Alexander JH
JAMA Cardiol; 2019 Aug; 4(8):747-755. PubMed ID: 31215979
[TBL] [Abstract][Full Text] [Related]
18. Double or triple antithrombotic therapy after coronary stenting and atrial fibrillation: A systematic review and meta-analysis of randomized clinical trials.
Andò G; Costa F
Int J Cardiol; 2020 Mar; 302():95-102. PubMed ID: 31924397
[TBL] [Abstract][Full Text] [Related]
19. Double or Triple Antithrombotic Treatment in Atrial Fibrillation Patients with Acute Myocardial Infarction Undergoing Percutaneous Coronary Intervention.
Benetou DR; Varlamos C; Mpahara A; Alexopoulos D
Am J Cardiovasc Drugs; 2021 Jan; 21(1):11-20. PubMed ID: 32170515
[TBL] [Abstract][Full Text] [Related]
20. [Antithrombotic Therapy in Patients with Acute Coronary Syndrome and Atrial Fibrillation].
Darius H
Dtsch Med Wochenschr; 2020 Jul; 145(14):978-986. PubMed ID: 32668469
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
